Saturday, September 23, 2023
Saturday, September 23, 2023

Endologix Receives FDA Approval of the DETOUR System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the DETOUR System to treat patients with complex peripheral arterial disease (PAD).

Over 8.5 million Americans are affected by PAD. This condition can cause significant pain, reduced mobility, and even amputation. At present, patients with long blockages of the superficial femoral artery (SFA) have limited treatment options. The recommended therapy is open surgical bypass, which is invasive, has a high early complication rate, and requires prolonged recovery. Endovascular treatments are feasible in selected patients but have limited patency.

Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg. This approach is particularly effective for patients with long lesions (20cm-46cm in length), those that have already undergone failed endovascular procedures, or those that may be sub-optimal candidates for open surgical bypass.

“We are delighted to receive FDA approval of the DETOUR System,” said Matt Thompson, MD, President, and CEO of Endologix. “PTAB therapy represents a significant step forward for patients with complex PAD, they have long needed a more effective and less invasive treatment option for long lesions of the SFA. We are proud to be pioneering this novel approach and continuing to innovate on behalf of patients. We look forward to launching this new therapy in the U.S. through a targeted market release in the coming weeks.”

With the introduction of the PTAB therapy, Endologix continues to build on its legacy of disruptive vascular therapies to improve patient outcomes. The DETOUR System represents a breakthrough in the treatment of PAD, and the company is committed to focusing on patients with the most pressing unmet clinical needs.

SourceENDOLOGIX
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Giorgio Ninzoli, President of Lipogems International. "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."

Stryker’s Triathlon Tritanium Baseplate Marks a Decade of Positive Patient Impact

Marking its 10th anniversary, the Triathlon Tritanium baseplate is designed with Stryker Orthopaedic Modeling and Analytics (SOMA) and enabled by Stryker's proprietary additive manufacturing technology.

Medtronic Diabetes Announces CE Mark for New Simplera™ CGM with Disposable All-in-one Design

The company's newest Simplera™ CGM is 50% smaller than its previous generation with a simple insertion and improved user experience

Study Outcomes Could Provide Insights Into New Targeted Treatments to Manage this Challenging Disease

The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies reports NICO.

Henkel Joins with MedTech Europe to Drive Innovation In the Medical Technology Industry

Henkel has a long history of supporting the medical technology industry with its advanced adhesive and surface solutions. Through this, Henkel and MedTech Europe will collaborate on various initiatives such as supporting research and development projects, driving thought leadership and engaging in industry forums.

By using this website you agree to accept Medical Device News Magazine Privacy Policy